Logo

American Heart Association

  1
  0


Final ID: 144

Mobile Stroke Unit Management and Outcomes in Undifferentiated Patients with Stroke-Like Symptoms in the Prehospital Setting: A Nationwide Cohort Study

Abstract Body: Introduction: Prospective, controlled clinical trials have suggested that prehospital management in a mobile stroke unit (MSU) improves functional outcomes in intravenous (IV) thrombolysis-eligible patients. However, because MSUs are dispatched prior to knowledge of the diagnosis, an examination of their real-world effectiveness must include all patients for whom stroke is suspected. The objective of this study was to determine the association between MSU management vs. EMS management and outcomes in all patients with suspected stroke in the prehospital setting.

Methods: We performed a retrospective, observational, cohort study from the American Heart Association’s Get With The Guidelines®-Stroke (GWTG-Stroke) Program between August 1st 2018 and January 31st 2023. At participating hospitals receiving both MSU-managed and standard EMS-managed patients, all patients with stroke-like symptoms in the prehospital setting were analyzed. The primary efficacy end point was the level of global disability assessed with the utility-weighted modified Rankin Scale (UW-mRS; rage 0.00 – 1.00). The secondary efficacy end point was ambulatory status. The co-primary safety end points were symptomatic intracranial hemorrhage (sICH) and in-hospital mortality.

Results: Of 108,684 patients (median age 73 [Q1,Q3: 62,83]; 51.2% female), 4,218 (3.9%) received prehospital management in an MSU. Prehospital management in an MSU was associated with a better score on the UW-mRS at discharge (adjusted mean difference 0.05 [95% CI: 0.03 – 0.06]) and a higher likelihood of independent ambulation at discharge (51.0% [1,521/2,985] vs. 47.8% [31,450/79,699]; aRR 1.11 [95% CI: 1.08 – 1.15]; adjusted risk difference 5.2% [95% CI: 3.7 to 6.8]). There was no statistically significant difference in sICH (4.0% vs. 4.1%; aRR 1.02 [95% CI: 0.82 – 1.25]). There was a lower rate of in-hospital mortality (6.4% vs. 8.7%; aRR: 0.78 [95% CI: 0.71 to 0.87]) in MSU-treated patients.

Conclusions: Among patients with stroke-like symptoms in the prehospital setting, prehospital management in an MSU compared with EMS management was associated with a significantly lower level of global disability. These findings support policy efforts to expand access to MSU care in the United States.
  • Mac Grory, Brian  ( Duke University School of Medicine , Durham , North Carolina , United States )
  • Sheth, Kevin  ( YALE UNIVERSITY SCHOOL OF MEDICINE , New Haven , Connecticut , United States )
  • Schwamm, Lee  ( Yale School of Medicine , New Haven , Connecticut , United States )
  • Smith, Eric  ( UNIVERSITY OF CALGARY , Calgary , Alberta , Canada )
  • Bhatt, Deepak  ( Mount Sinai Fuster Heart Hospital , Scarsdale , New York , United States )
  • Fonarow, Gregg  ( UCLA MEDICAL CENTER , Los Angeles , California , United States )
  • Saver, Jeffrey  ( GEFFEN SCHOOL OF MEDICINE AT UCLA , Los Angeles , California , United States )
  • Xian, Ying  ( UTSW , Dallas , Texas , United States )
  • Grotta, James  ( Memorial Hermann Hospital , Houston , Texas , United States )
  • Sun, Jie-lena  ( Duke University School of Medicine , Durham , North Carolina , United States )
  • Alhanti, Brooke  ( Duke University , Durham , North Carolina , United States )
  • Lusk, Jay  ( Duke University School of Medicine , Durham , North Carolina , United States )
  • Li, Fan  ( Duke University , Durham , North Carolina , United States )
  • Adeoye, Opeolu  ( Washington University , Saint Louis , Missouri , United States )
  • Furie, Karen  ( Department of Neurology , Providence , Rhode Island , United States )
  • Hasan, David  ( Duke University , Durham , North Carolina , United States )
  • Messe, Steven  ( University of Pennsylvania , Philadelphia , Pennsylvania , United States )
  • Author Disclosures:
    Brian Mac Grory: DO have relevant financial relationships ; Research Funding (PI or named investigator):National Institutes of Health:Active (exists now) ; Research Funding (PI or named investigator):American Heart Association:Active (exists now) | Kevin Sheth: DO NOT have relevant financial relationships | Lee Schwamm: DO have relevant financial relationships ; Consultant:genentech:Active (exists now) ; Advisor:Penumbra:Past (completed) ; Consultant:medtronic:Active (exists now) | Eric Smith: DO NOT have relevant financial relationships | Deepak Bhatt: DO have relevant financial relationships ; Advisor:Angiowave, Bayer, Boehringer Ingelheim, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, High Enroll, Janssen, Level Ex, McKinsey, Medscape Cardiology, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Stasys:Active (exists now) ; Other (please indicate in the box next to the company name):Honoraria cont: Journal of the American College of Cardiology (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Oakstone CME (Course Director, Comprehensive Review of Interventional Cardiology), Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), WebMD (CME steering committees), Wiley (steering committee);:Active (exists now) ; Other (please indicate in the box next to the company name):Trustee: American College of Cardiology; Unfunded Research: FlowCo.:Active (exists now) ; Other (please indicate in the box next to the company name):Site Co-Investigator: Abbott, Biotronik, Boston Scientific, CSI, Endotronix, St. Jude Medical (now Abbott), Philips, SpectraWAVE, Svelte, Vascular Solutions;:Active (exists now) ; Royalties/Patent Beneficiary:Royalties: Elsevier (Editor, Braunwald’s Heart Disease);:Active (exists now) ; Research Funding (PI or named investigator):Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Alnylam, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor, Cleerly, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Otsuka, Owkin, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, Youngene, 89Bio;:Active (exists now) ; Royalties/Patent Beneficiary:Sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women's Hospital who assigned to Lexicon; neither I nor Brigham and Women's Hospital receive any income from this patent);:Active (exists now) ; Other (please indicate in the box next to the company name):Other: Clinical Cardiology (Deputy Editor);:Active (exists now) ; Other (please indicate in the box next to the company name):American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), CSL Behring (AHA lecture), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology),:Active (exists now) ; Other (please indicate in the box next to the company name):Data Monitoring Committees: Acesion Pharma, Assistance Publique-Hôpitaux de Paris, Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (Chair, PEITHO trial), Cleveland Clinic, Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo; for the ABILITY-DM trial, funded by Concept Medical; for ALLAY-HF, funded by Alleviant Medical), Novartis, Population Health Research Institute; Rutgers University (for the NIH-funded MINT Trial);:Active (exists now) ; Consultant:Broadview Ventures, GlaxoSmithKline, Hims, SFJ, Youngene:Active (exists now) ; Individual Stocks/Stock Options:Board of Directors: Angiowave (stock options), Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock):Active (exists now) ; Other (please indicate in the box next to the company name):Board of Directors: American Heart Association New York City, Angiowave (stock options), Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock):Active (exists now) | Gregg Fonarow: DO NOT have relevant financial relationships | Jeffrey Saver: DO have relevant financial relationships ; Consultant:Abbott:Active (exists now) ; Individual Stocks/Stock Options:Viz.ai:Active (exists now) ; Individual Stocks/Stock Options:Let's Get Proof:Active (exists now) ; Individual Stocks/Stock Options:Neuronics:Active (exists now) ; Consultant:Genentech:Expected (by end of conference) ; Consultant:Roche:Active (exists now) ; Consultant:Novo Nordisc:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) ; Consultant:BrainQ:Active (exists now) ; Consultant:Medtronic:Active (exists now) | Ying Xian: DO NOT have relevant financial relationships | James Grotta: DO have relevant financial relationships ; Consultant:Frazer Ltd:Active (exists now) ; Advisor:Prolong Pharma:Active (exists now) ; Advisor:Acticor:Active (exists now) ; Advisor:Diamedica:Active (exists now) | Jie-Lena Sun: DO NOT have relevant financial relationships | Brooke Alhanti: DO NOT have relevant financial relationships | Jay Lusk: DO NOT have relevant financial relationships | Fan Li: DO NOT have relevant financial relationships | Opeolu Adeoye: DO NOT have relevant financial relationships | Karen Furie: DO have relevant financial relationships ; Consultant:Janssen/BMS:Active (exists now) | David Hasan: DO NOT have relevant financial relationships | Steven Messe: DO NOT have relevant financial relationships
Meeting Info:
Session Info:

Cerebrovascular Systems of Care Oral Abstracts II

Friday, 02/07/2025 , 09:15AM - 10:45AM

Oral Abstract Session

More abstracts on this topic:
More abstracts from these authors:
Race-Ethnic Specific Hospital Arrival Time of Acute Ischemic Stroke by State in the U.S.

Chen Bing Yu, Xian Ying, Uchino Ken, Man Shumei, Sun Jie-lena, Fonarow Gregg, Alhanti Brooke, Mac Grory Brian, Smith Eric, Schwamm Lee, Bhatt Deepak, Saver Jeffrey

Derivation and Validation of the Get with the Guidelines®-Stroke Endovascular Thrombectomy Risk Scores

Lusk Jay, Bhatt Deepak, Saver Jeffrey, Mac Grory Brian, Brown Scott, Hassan Ameer, Albers Gregory, Fonarow Gregg, Schwamm Lee, Messe Steven, Smith Eric, Hasan David

You have to be authorized to contact abstract author. Please, Login
Not Available

Readers' Comments

We encourage you to enter the discussion by posting your comments and questions below.

Presenters will be notified of your post so that they can respond as appropriate.

This discussion platform is provided to foster engagement, and simulate conversation and knowledge sharing.

 

You have to be authorized to post a comment. Please, Login or Signup.


   Rate this abstract  (Maximum characters: 500)